Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
k thx :)
which one ed?
Mach, this from the microcap basement board, says convertibles are 'out of the way' fwiw
From: Ted M 12/5/2006 12:56:18 PM
To: ~protege who wrote (1979) Read Replies (1) of 2170
PLRS coming to life--presentation next Tuesday..This is a stem cell company that sounds like it is doing some remarkable things, with a small market cap...with convertible out of the way, this may make another move up at least in the short term..
Pluristem to Present at Annual Meeting of American Society of Hematology: Breakthrough Method Improves Engraftment of Umbilical Cord Blood in Treating Severe Blood Disorders
Tuesday December 5, 7:30 am ET
NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB: PLRS - News) today announced that it has been chosen to present at the annual meeting of the American Society of Hematology on December 10th in Orlando, Florida. Hematology experts from around the world will gather to discuss the latest developments in their field. Pluristem will present how it has overcome the major barrier resulting from pre-selection and separation of cord blood early hematopoietic stem cells (HSC), and their breakthrough process that improves engraftment of Umbilical Cord Blood when treating severe blood disorders.
The current methodologies used in HSC expansion protocols apply an enrichment stage of rare subpopulation source cells defined as CD34 positive cells. These CD34 cells are pre-selected from a large and mixed population of mononuclear cells. This process results in a substantial loss of source cells and targets a cell population that may not represent the earliest extractable population of HSC.
The Pluristem developed method extracts and preserves for use a much larger number of CD34 positive cells than current methods. Pluristem's advanced approach to cell selection and separation was accomplished by using non-selected mononuclear cells (MNC) in the Company's U.S. patented three-dimensional scaffolding PluriX bioreactor. The PluriX uses flow-through co-culture techniques simulating the physiological environment within the bone marrow. The efficacy of the PluriX in expanding non-selected MNC is based upon the selective adherence of HSC and early progenitor cells from the general MNC pool to the 3-D stroma cells cultures within the PluriX system.
Zami Aberman, Pluristem CEO states, "Our ability to improve the engraftment of Umbilical Cord Blood in treating severe blood disorders, as presented recently in the ISEH conference in Minneapolis, has attracted attention in the hematology community. We are honored to have been chosen to present at this meeting of prestigious hematology experts. Our breakthrough process could lead to the wider use of Umbilical Cord Blood in bone marrow transplants and in treating various types of blood cancer benefiting 100,000 people annually."
The American Society of Hematology 48th Annual Meeting and Exposition is being held December 9-12, 2006 at the Orange County Convention Center, Orlando FL.
About Pluristem
Pluristem Life Systems, Inc. is life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
www.pluristem.com
Report TOU Violation Recommend This Post
UBDT .04 x .045 a 50k buy L 2 improving 2x3 now
PLRS i added a few today, hoping this might be a catalyst for higher prices
Pluristem to Present at Annual Meeting of American Society of Hematology: Breakthrough Method Improves Engraftment of Umbilical Cord Blood in Treating Severe Blood Disorders
Pluristem Life Systems, Inc. (OTCBB: PLRS) today announced that it has been chosen to present at the annual meeting of the American Society of Hematology on December 10th in Orlando, Florida. Hematology experts from around the world will gather to discuss the latest developments in their field. Pluristem will present how it has overcome the major barrier resulting from pre-selection and separation of cord blood early hematopoietic stem cells (HSC), and their breakthrough process that improves engraftment of Umbilical Cord Blood when treating severe blood disorders.
The current methodologies used in HSC expansion protocols apply an enrichment stage of rare subpopulation source cells defined as CD34 positive cells. These CD34 cells are pre-selected from a large and mixed population of mononuclear cells. This process results in a substantial loss of source cells and targets a cell population that may not represent the earliest extractable population of HSC.
The Pluristem developed method extracts and preserves for use a much larger number of CD34 positive cells than current methods. Pluristem's advanced approach to cell selection and separation was accomplished by using non-selected mononuclear cells (MNC) in the Company's U.S. patented three-dimensional scaffolding PluriX bioreactor. The PluriX uses flow-through co-culture techniques simulating the physiological environment within the bone marrow. The efficacy of the PluriX in expanding non-selected MNC is based upon the selective adherence of HSC and early progenitor cells from the general MNC pool to the 3-D stroma cells cultures within the PluriX system.
Zami Aberman, Pluristem CEO states, "Our ability to improve the engraftment of Umbilical Cord Blood in treating severe blood disorders, as presented recently in the ISEH conference in Minneapolis, has attracted attention in the hematology community. We are honored to have been chosen to present at this meeting of prestigious hematology experts. Our breakthrough process could lead to the wider use of Umbilical Cord Blood in bone marrow transplants and in treating various types of blood cancer benefiting 100,000 people annually."
The American Society of Hematology 48th Annual Meeting and Exposition is being held December 9-12, 2006 at the Orange County Convention Center, Orlando FL.
About Pluristem
METP on low vol .05x .065 1x2
not sure about that, have not followed squm, will take a look
hi mick, going well thx, hope all is well with you and yours :)
LDTI they whacked it , may not be as easy to get back in if it's as thin as it looks
Yep, gotta love it
That and it was one of the few i sold 11/30 for a tax loss to buy back at the end of the year lol
ETLC - Ledbed i think
I heard a rumor(completely unsubstantiated) that someone sold some CAML that they shouldn't have. If true I hoping they have to buy back on the open market. Other than that just waiting for them to seal a deal :)
METP, CAML, AEGP, DTEK, UBDT to name a few :)
Well, you could do lots worse pat has been amazing at finding sleepers.
SENS correct now sntx, got a few on this news jic
That's me in the back rotf :)
Weebee, u got that right, that pos clyp moved to .51 :)
Sentex Sensing Technology, Inc. Obtains Financing Arrangement in Europe
CLEVELAND, Dec. 7, 2006 (PRIME NEWSWIRE) -- Henrik Rubinstein, President and Bob Kendall, Chairman and Treasurer of Sentex Sensing Technology, Inc. (OTCBB:SNTX) (http://www.sentextech.com) stated today that they signed a Financing Agreement with Euro Partner Capital BV.
This Agreement states that Sentex Sensing Technologies would participate in a 10 million Euro offering to be organized 1st quarter 2007. Under the agreement Euro Partners will offer by prospectus for accredited investors investing in Global Positioning with GHLT:PK, Biometric Technology with SNTX:OB and several telecom entities. Of the "firm commitment" generated funds, Sentex will receive some 1.5 million dollars for the discounted shares of SNTX. The average selling price EP will buy from SNTX will be in excess of $0.10 cents a share. Euro partners may participate further. The contact was organized by Balmoral Financial Services of Ohio. The offering will be available by Christmas in Dutch and English only in the European Union. It is not available in the United States.
About Sentex Sensing Technology, Inc.
Sentex Sensing Technology, Inc. is one of the leading multimodal-biometric technology companies. Sentex provides fingerprint, facial, iris and voice biometric technologies, as well as systems, and critical system components that empower the identification of individuals in large-scale ID and ID management programs. The Company's offerings include access control, computer based internet authentification, biometric smart cards and services for biometric data capture, mobile POS systems, and backend standards-based modules and software components for biometric matching and data mining. Sentex products are used to conduct background checks, secured travel and commerce via secure identification documents, prevent identity fraud in large-scale government and civil ID programs, and control access to secure areas and networks.
About Balmoral Financial Services Companies
In operation since 1986, Balmoral (http://www.balmoralfinancial.com), an Ohio corporation, is a niche financial services company that specializes in identifying merger candidates and placing these transactions with American companies. Balmoral provides private entrepreneurs and public companies M&A, Bank Guarantees, Documentary Credit, International Promissory Notes, and PIPE financing services.
About Euro Partner Capital BV
Euro Partner Capital BV's (www.europartner.nu) head office in Holland sells discounted securities under EU law to accredited investors under a prospectus in Dutch. Euro Partners USA Inc. is its USA Subsidiary.
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Sentex, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.
CONTACT: Sentex Sensing Technologies Inc.
Marketing:
Maryann Kusa
(216) 687-0289, ext. 125
Fax: (216) 687-0298
mb@sentextech.com
SPCI
SPCI took a little bite also and added to my spci pile. When it's ready it can have some nice runs :)
GARM added a few, interesting post from the kitchen board on SI
From: Ted M 12/5/2006 12:35:18 PM
of 2153
GARM, Recyclenet. Internet websites bringing together scrap dealers. What is incredible is that they claim over 3.8 unique users each month, and they are profitable, almost no debt, and reporting. Selling at .04. IF they get funding for their SEC-MAT (Nasdaq-like) system which automates bids/asks then watch out..This looks like a sincere company quietly going about building a monster. Takeover candidate down the road.
METP Yes and SEAB, one of the mm at .15, closed
.023,.025,.025 x .029, .03, .03 .055, 2.00
NRGX had some form 4s today fwiw
I guess you are correct. METP could get nice this week. You follow CAML, another one to put on watch
MSSI 8k today fwiw
Chart -
Reminder: Check For: ---> Dilution - Splits - News
>
OSSG hmm .05 wall almost gone, grabbed a few
That your 50k? on metp
CTTJ passed at .0012 due to clyp :(
HTRE ty bob H3's ``Battle at the Apollo'' is the Talk of the Town
Business Wire - November 30, 2006 09:52
XBOX 360 vs. PlayStation3 on H3TV will be focus of H3's Weekly Conference Call Today at Noon
NEW YORK, Nov 30, 2006 (BUSINESS WIRE) -- H3Enterprises, Inc. (OTC:HTRE) has announced that the first ever face-off for Gaming Console supremacy between Microsoft's (NASDAQ:MSFT) XBOX 360 and Sony's (NYSE:SNE) PlayStation3 has become the hottest ticket in New York. Details surrounding this event will be discussed during H3's weekly Conference Call scheduled for 12:00 Noon Eastern. All interested parties are invited to participate by calling 319-256-0100 (Pass code 966407).
H3's "Gaming Console Challenge" is set to take place live at Harlem's Apollo Theater on H3's revolutionary H3TV, a multi-functional computerized television display with 1080p resolution designed to be the LCD flat screen of the "Hip Hop Generation", and will be utilized in all of H3's HipHopSodaShops. H3TV is the first flat screen on the market that is truly customized and contains a variety of features designed specifically for video gamers. The competition is set for Wednesday, December 6th beginning at 2:00 PM.
"The response we're receiving from the media, the investment community, the entertainment industry, as well as Gamers everywhere has been overwhelming," said H3's Chief Communications Officer and CyberSports superstar Adrian "Hollywood" Walton. "We're getting all types of media requests as well as inquiries from analysts and brokers with practically every major investment firm on Wall Street. Our Celebrity A-List is also growing everyday and all of this will be discussed on the call."
"The H3TV Challenge gives all of us the chance to witness the same game being played on the same monitor at the same time on competing video gaming systems," continued Walton. "Everyone playing and watching will get an up-close
Chart -
Reminder: Check For: ---> Dilution - Splits - News
>
Chart -
Reminder: Check For: ---> Dilution - Splits - News
>
CAML it moves on air for sure
IMHI was trying to buy this am at .35. AMTD disabled online trading for it and i was too lazy to call. Really getting tired of them protecting me this way.
Yes i do :)
They still have a deal in the works?
IPLY don't look :(
sweet :)
IPLY again :)